Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEXL -- Ignore unavailable to you. Want to Upgrade?

To: SIer formerly known as Joe B. who wrote (1370)	5/7/1998 9:53:00 PM
From: bob jaremsek	Read Replies (1) \| Respond to of 1704

Editorial in today's Providence Journal by Dr.Jerome Groopman on the cancer discovery at Harvard which has been the rage d' jour. Groopman writes of his patients calling him at all hours offering themselves in hopes of being treated by the "Harvard Cocktail"...(my quotes). His own mother is in remission in her fight with breast cancer ..."her voice grew heavy with concern when I seemed restrained in my enthusiam over the new developments." "I explainded to my mother, and to my patients...that science rarely leaps forward with a single epiphany. Rather, it progresses in painstaking increments, each advance facing a new set of obstacles, some expected and some unexpected, before success." "Human cancers are more diverse, and more adept at becoming resistant to therapies....furthermore, people might prove allergic to the proteins. Or it might be hard to sustain adequate amounts of the proteins in the bloodstream for them to have their desired effect." "It would be foolhardy for Congress or industry to ignore other research and look only to the strategy of blocking blood vessels. The fianancing of science works like any other investment: Steady returns come with a diversified portfolio." Dr. Jerome Groopman, professor of medicine at Harvard, also happens to be a board member of VIMRX. Groopman has laid out the science, business and future of cancer research over the next few years....VIMRX, ISOLEX, NEXELL, INNOVIR.